Leerraum

Events und Webinare

Beschleunigung der klinischen Entwicklung mithilfe von Studien mit einem Fokus auf Design, Diversität und Digitalisierung – in der Onkologie und in anderen Bereichen

16 May 10am EDT (NA) / 3pm BST (UK) / 4pm CEST (EU-Central) Duration: 1 hour Ansehen
Webinar overview

In diesem dynamischen Webinar erklären Experten, wie die klinische Entwicklung beschleunigt und die Kapitalrendite (ROI) mithilfe eines „3-D“-Ansatzes für Studien mit einem Fokus auf Design, Diversität und Digitalisierung maximiert werden kann.

Oncology trials present unique challenges and will be the focal point for this discussion, but the key insights the speakers will cover are applicable to a wide range of therapeutic areas. Therefore, attendance is recommended across all therapeutic areas, ranging from cardiovascular to neuroscience to rare disease and, in fact, any enrollment-challenged indications.

The need to improve geographical, racial, ethnic and other forms of diversity and inclusion in trials -including new legislation and regulatory guidance documents to spur adoption of diverse trials - has been at the forefront of the industry for several years. The speakers will draw insights from what has worked and what still needs to be done, and how new tools, digital and mobile health and other innovative approaches can lead the way. Again, oncology poses special challenges due to the rarity of patients in certain indications and limitations on the ways in which recruitment can occur, particularly during earlier trial phases and where patient-centric approaches may be hard to implement.

With so many recent advances in the application of "big data" strategies and artificial intelligence to trial design and execution, the speakers will discuss concrete ways in which these novel approaches have impacted trials and pipelines. With the perspective of a leading oncology CRO, the speakers will review case studies and aggregate insights with an eye toward improving trial outcomes and performance against key performance indicators (KPIs) by working within an ecosystem where the CRO, investigator sites, patient advocacy groups and industry-leading partners all contribute to a shared mission of accelerating getting new treatments to patients in need.

Learnings

  • Key lessons in applying novel strategies to boost DEI from real-world examples to support trial designs that will enhance ROI and adherence to KPIs

  • The importance of incorporating new data strategies and the impact of artificial intelligence on trial design and execution will be discussed in the form of case studies and insights from around the industry


Speakers
item0
Dr. Geoffrey Kannan PhD, MD, Executive Medical Director, Oncology Therapeutic Area
item1
Brian Dolan Vice President, Artificial Intelligence and Machine Learning
item2
Alicia M. Baker McDowell DRSc, MS, EMBA, Head of Regulatory Strategy and Product Development Consulting
item3
Melissa Harris Head of Global Patient Recruitment and Engagement
item4
Ryan Kirby Associate Director, Digital Health and Innovation